Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Return on Assets (2021 - 2025)

SAB Biotherapeutics (SABS) has disclosed Return on Assets for 5 consecutive years, with 0.05% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Assets rose 61.0% year-over-year to 0.05%, compared with a TTM value of 0.05% through Dec 2025, up 61.0%, and an annual FY2025 reading of 0.44%, up 21.0% over the prior year.
  • Return on Assets was 0.05% for Q4 2025 at SAB Biotherapeutics, up from 0.18% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.05% in Q3 2021 and bottomed at 0.88% in Q2 2025.
  • Average Return on Assets over 5 years is 0.49%, with a median of 0.55% recorded in 2024.
  • The sharpest move saw Return on Assets tumbled -45bps in 2023, then skyrocketed 61bps in 2025.
  • Year by year, Return on Assets stood at 0.17% in 2021, then crashed by -109bps to 0.36% in 2022, then crashed by -108bps to 0.75% in 2023, then grew by 11bps to 0.67% in 2024, then soared by 92bps to 0.05% in 2025.
  • Business Quant data shows Return on Assets for SABS at 0.05% in Q4 2025, 0.18% in Q3 2025, and 0.88% in Q2 2025.